Complement function in mAb-mediated cancer immunotherapy.

Trends in immunology ·Vol. 25 ·No. 3 ·2004-03-00 ·Pages 158-64

Gelderman KA, Tomlinson S, Ross GD, Gorter A

Abstract

暂无摘要

MeSH Terms

Adjuvants, Immunologic/pharmacology,therapeutic use Animals Antibodies, Monoclonal/pharmacology,therapeutic use Antibody-Dependent Cell Cytotoxicity Complement Activation/drug effects Complement C3b/physiology Complement Membrane Attack Complex/physiology Complement System Proteins/physiology Cytotoxicity, Immunologic/drug effects Drug Design Glucans/pharmacology,therapeutic use Humans Immunotherapy Macrophage-1 Antigen/immunology Membrane Proteins/antagonists & inhibitors,physiology Mice Models, Immunological Neoplasm Proteins/antagonists & inhibitors,physiology Neoplasms/immunology,therapy Neoplasms, Experimental/immunology,therapy beta-Glucans

Chemicals

Adjuvants, Immunologic Antibodies, Monoclonal Complement Membrane Attack Complex Glucans Macrophage-1 Antigen Membrane Proteins Neoplasm Proteins beta-Glucans Complement C3b Complement System Proteins beta-1,3-glucan

Authors & Affiliations

4 authors, click to expand affiliations / ORCID

Gelderman Kyra A

Department of Pathology L1-Q, Leiden University Medical Center, Postbox 9600, 2300 RC Leiden, The Netherlands.

Tomlinson Stephen

Ross Gordon D

Gorter Arko

Article Info

Journal

Trends in immunology

Abbr.

Trends Immunol

ISSN

1471-4906

DOI

10.1016/j.it.2004.01.008

Published

2004-03-00

Pages

158-64

Language

English

Region

England

NLM ID

100966032

Subset

External Links

PubMed source DOI: 10.1016/j.it.2004.01.008 View journal details

Analysis Services

Complement function in mAb-mediated cancer immunotherapy.

Contact

WeChat Official Account